ACMR · ACM Research

The thesis

ACM Research's third-quarter gross margin of 41.6% fell under management's 42% floor even as revenue rose 36.6% and the 2026 outlook was raised, so the shares are more likely to lag the S&P 500 over three months. Fourth-quarter results, due in 2027, settle whether revenue growth reaches earnings.

On 5 November 2026 the company reported third-quarter revenue of $367.7 million, up from $269.2 million a year earlier. That topped the $360–$365 million range it previewed on 28 October 2026. It raised the fiscal 2026 revenue outlook to $1.24–$1.28 billion from $1.125–$1.175 billion.

Non-GAAP gross margin (adjusted to exclude stock-based pay and similar items) was 41.6%, against 42.1% a year earlier and below the 42%–48% long-term range. Management cited product mix, currency and an inventory provision.

The shares closed at $39.31 on 5 November 2026, rose to $44.61 on 6 November 2026 and $49.75 on 9 November 2026, and closed at $49.88 on 12 November 2026. That recovery leaves them 38.0% below the close of $80.42 on 14 August 2026.

Bullish and bearish views on ACM Research, Inc.

The bull case on ACM Research, Inc. (ACMR), in brief: revenue beat the company's own preview. The bear case: gross margin fell below the floor.

Bull case

• Revenue beat the company's own preview. Third-quarter revenue of $367.7 million, up 36.6%, topped the $360–$365 million range given on 28 October 2026. Shipments were $343.5 million, up 30.6%, above the preliminary $335–$340 million range.
• Full-year outlook rose sharply. The 5 November 2026 release lifted fiscal 2026 revenue guidance to $1.24–$1.28 billion, or 38%–42% growth. A news headline that day cited an analyst estimate of $1.173 billion.
• Operating leverage improved. Non-GAAP operating margin was 18.0% against 13.6% a year earlier. Non-GAAP operating income was $66.2 million.
• Orders run ahead of sales. ACM Shanghai reported 17.1 billion renminbi of backlog on 29 September 2026, up 88.2% from a year earlier. The company expects strong shipment growth in the fourth quarter.
• The shares rebounded after the report. Closes rose from $39.31 on 5 November 2026 to $52.43 on 11 November 2026, the highest close in that span, before easing to $49.88 on 12 November 2026.

Bear case

• Gross margin fell below the floor. Non-GAAP gross margin was 41.6% against 42.1% a year earlier, under the 42%–48% range, per the 5 November 2026 release. Management expects only modest sequential improvement in the fourth quarter.
• Reported earnings trail adjusted earnings. GAAP diluted earnings per share were $0.02 against $0.52 a year earlier, while non-GAAP diluted earnings were $0.55, per the 5 November 2026 release.
• Insiders sold near the highs. SEC Form 4 filings show David Wang, a director and 10% owner, sold 140,000 shares at an average of $75.93 on 8 September to 9 September 2026. Mark McKechnie sold 55,199 shares at an average of $77.27 on 20 August 2026, and director Haiping Dun sold 5,000 shares at an average of $81.13 on 18 August 2026. All three sales were under Rule 10b5-1 plans, which are pre-scheduled selling plans.
• The shares remain far below their averages. The 12 November 2026 close of $49.88 sits below the 50-day average of $63.19 and the 200-day average of $68.32, and 60.8% below the 52-week intraday high.
• Dilution and export controls remain open. ACM Shanghai's Hong Kong share offering was authorised on 26 May 2026 for 24 months with no pricing date. ACM subsidiaries have been inside the US export-control net since December 2024.

Price setup

The shares closed at $49.88 on 12 November 2026. The 52-week intraday high is $127.19 on 30 June 2026, and the 52-week closing low is $29.67 on 20 November 2025. The three-month change is −38.0%.

The 50-day average of closes is $63.19 and the 200-day average is $68.32, both as of 12 November 2026. Both sit above the last close, and the 50-day average is below the 200-day, so the shorter trend still points down.

Over the six sessions from 5 November to 12 November 2026, closes ran between $39.31 and $52.43. The market priced a raised outlook into the shares at roughly a third of the June peak, which leaves the gross margin shortfall and China policy risk as the discount the shares carry.

The company filed its 10-Q with the SEC on 6 November 2026. No earnings date falls inside the next 30 days.

Catalysts ahead

• No fixed date: Hong Kong pricing or listing application for the ACM Shanghai share offering. The board can price anytime inside the 24-month window opened on 26 May 2026; size and discount set the dilution.
• No fixed date: US export-control or Entity List action touching ACM Research (Shanghai). Revenue is concentrated in China fabs, and the subsidiaries have been inside the US export-control net since December 2024.
• 2027 (date not announced): Fourth-quarter and full-year 2026 results. The next gross margin reading against the 41.6% of the third quarter, and a test of whether the $1.24–$1.28 billion outlook is met.

What would change the view

A daily close above $68.35, just above the 200-day average of closes, which would show the shares leading the S&P 500 again; or fourth-quarter non-GAAP gross margin back inside the 42%–48% long-term range.

What it trades with

ACM's tools serve China wafer fabs, so the shares track China localization and memory capital spending more than US foundry orders. ACM Shanghai trades separately on the STAR Market (688082) in Chinese hours and can reprice before the US line opens. Its backlog is reported in renminbi under PRC accounting, over a different entity perimeter than the parent's US-dollar non-GAAP results. MarketBeat gave a beta of 2.09 on 13 October 2026, which means broad semiconductor selloffs have tended to hit the shares harder than the market.